# TME Pharma

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/TME_Pharma
> Markdown URL: https://mediated.wiki/source/TME_Pharma.md
> Source: https://en.wikipedia.org/wiki/TME_Pharma
> Source revision: 1284528964
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**TME Pharma**, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in [Berlin, Germany](/source/Berlin,_Germany) which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).

TME Pharma develops drugs using technology yielding [L-RNA molecules](/source/L-Ribonucleic_acid_aptamer), which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers,[2][3] from *Spiegel*, the German word for "mirror."

The L-RNA are resistant to the natural RNA [nuclease](/source/Nuclease) enzymes.[4]

## Products

Some Spiegelmer candidates were in clinical trials.

A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets [CXCL12](/source/Stromal_cell-derived_factor_1) (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.[5][6][7][8]

A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive [diabetic nephropathy](/source/Diabetic_nephropathy).[9] Favorable results were reported in June 2014 in a company press release.[10] NOX-E36 targets [MCP-1](/source/CCL2), also called [CCL2](/source/CCL2).[4]

A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of [anemia](/source/Anemia) of chronic disease.[11][12]

## References

1. [Investors](https://www.noxxon.com/index.php?option=com_content&view=article&id=67&Itemid=571). Noxxon.com. Retrieved on 2018-02-14.

1. Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". *Curr Opin Drug Discov Dev*. **6** (2): 253–61. [PMID 12669461](https://pubmed.ncbi.nlm.nih.gov/12669461)

1. Eulberg D (2006), "Spiegelmers for Therapeutic Applications" (in German), *The Aptamer Handbook*, WILEY-VCH, pp. 417–42, ISBN 3-527-31059-2

1. ["News Review: Aram Mangasarian, Noxxon Pharma AG"](https://web.archive.org/web/20130524083207/http://www.pharmatelevision.com/Video/999-PTVNewsReviewAramMangasarianNOXXONPharmaAG.aspx). pharmatelevision.com. Archived from [the original](http://www.pharmatelevision.com/Video/999-PTVNewsReviewAramMangasarianNOXXONPharmaAG.aspx) on 2013-05-24. Retrieved 2013-07-16.

1. ["Noxxon Presents Top-Line Data from Nox-A12 Monotherapy Part of Ongoing Metastatic Colorectal and Pancreatic Cancer Trial"](https://www.noxxon.com/downloads/pressrel/2018-10-02_NOXXON_Presentation_NOX-A12_Trial_Data_Part1_New_York_EN.pdf). Noxxon. October 2, 2018.

1. ["Noxxon's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference"](http://www.noxxon.com/downloads/pressrel/2014-06-02_NOXXONs_Emapticap_Pegol_Study_Selected_for_Late_Breaking_Clinical_Trials_Symposium.pdf). Noxxon. June 2, 2014.

1. Schwoebel F, etal (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". *Blood*. **121** (12): 2311–5. [doi:10.1182/blood-2012-09-456756](https://doi.org/10.1182/blood-2012-09-456756). [PMC 3606066](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606066). [PMID 23349391](https://pubmed.ncbi.nlm.nih.gov/23349391)

---
Adapted from the Wikipedia article [TME Pharma](https://en.wikipedia.org/wiki/TME_Pharma) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/TME_Pharma?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.